What happened
The single-arm pilot, led by Ai-Ling Lin, gave low-dose daily rapamycin for 4 weeks to healthy adults aged 45 to 65. Cerebral blood flow improved in APOE4 carriers, but not in non-carriers. Metabolic, inflammatory and microbiome profiles were also modulated.
The study was published 6 November 2026.
Why it matters
APOE4 carriers are the group most in need of early prevention, and blood flow is one of the earliest things to change before symptoms. A drug that moves it in four weeks is a signal worth following — but a signal is not prevention.
What comes next
A controlled trial is needed: this pilot had no placebo group and lasted only weeks. What matters is whether blood-flow gains turn into memory protection over years.
Pilot, single-arm, no placebo group, four weeks; it measures blood flow, not memory or Alzheimer's prevention. It does not show that rapamycin prevents the disease. Different from Monday's PEARL story and from the transplant data excluded this week.